{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Status:
Investigational
Class:
PROTEIN
Status:
Investigational
Source:
NCT03472027: Phase 1 Interventional Completed Melanoma
(2017)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT03591614: Early Phase 1 Interventional Withdrawn Monoclonal Gammopathy
(2023)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:ifinatamab deruxtecan [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT03755167: Phase 2 Interventional Suspended Amyotrophic Lateral Sclerosis (ALS)
(2018)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT03860038: Phase 2 Interventional Active, not recruiting Multiple Myeloma in Relapse
(2019)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT00590824: Phase 2 Interventional Completed Melanoma
(2007)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:pegenzileukin [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT03869190: Phase 1/Phase 2 Interventional Active, not recruiting Urothelial Carcinoma
(2019)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT03647800: Phase 1 Interventional Unknown status AML
(2018)
Source URL:
Class:
PROTEIN
